ASP 7147

Drug Profile

ASP 7147

Alternative Names: ASP7147

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Astellas Pharma
  • Developer Astellas Pharma; Seldar Pharma
  • Class Irritable bowel syndrome therapies
  • Mechanism of Action Bombesin BB2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Irritable bowel syndrome

Most Recent Events

  • 13 Apr 2016 Phase-II development for Irritable bowel syndrome is ongoing in USA
  • 01 Jul 2014 Seldar Pharma completes a phase II trial in Irritable bowel syndrome in USA (NCT01896583)
  • 26 Nov 2013 Phase-II clinical trials in Irritable bowel syndrome in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top